KRAS and GNAS mutations are associated with a greater risk of malignancy, differentiating high-risk IPMN from MCN.17MUC2 and intestinal markers can be used to differentiate PanIN from intestinal IPMN and change management plans.18 This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.